表皮生长因子受体小分子抑制剂埃罗替尼应用研究进展

表皮生长因子受体(EGFR)异常表达与肿瘤细胞的增殖、血管生成、肿瘤侵袭、转移及细胞凋亡的抑制有关.EGFR小分子抑制剂埃罗替尼(erlotinib)是一种表皮生长因子酪氨酸激酶可逆性抑制剂,通过抑制酪氨酸激酶的磷酸化,阻断信号转导,抑制肿瘤生长.埃罗替尼在治疗非小细胞肺癌中有良好作用,在神经胶质瘤及其他EGFR异常表达的肿瘤中尚未显示显著疗效.埃罗替尼和其他抗肿瘤药物联合应用越来越受到重视,埃罗替尼和其他靶向制剂或化疗药的联合治疗方案可能成为未来肿瘤治疗的一个重要策略.

Translational research progress in inhibitory effect of EGFR targeting small molecular inhibitor Tarceva on tumor cells

Large quantities of recent researches show abnormal expression of epidermal growth factor receptor (EGFR)in different solid tumors. An especial relationship between EGFR expression and tumor cell proliferation, angiogenesis, invasive ability metastasis and apoptosis has been established. Tarceva, is an epidermal growth factor tyrosine kinase reversible inhibitor, which blocks signal transduction by inhibiting the tyrosine kinase phosphorylation and thus inhibits tumor growth. Tarceva is now proved to have certain therapeutic effects on non-small cell lung carcinoma ( NSCLC ), however, it has not shown a convincing effect when applied in gli omas and other tumors. Now the research of the combination with Tarceva and other anti-tumor drugs has come into the focus. Combination therapy with Tarceva and other chemotherapeutic drugs or other means might be an effective alternative.